PCSK9 inhibitor evolocumab not associated with decline in memory or cognitive function

(Brigham and Women's Hospital) New research led by the TIMI Study Group at Brigham and Women's Hospital in collaboration with Brown University and the University of Geneva reassuringly finds no association between the use of the PCSK9 inhibitor evolocumab and a decline in memory or cognitive function.